Aubra Eq Kit
Product Images NDC 50102-220

10 FDA label images from Afaxys Pharma, Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Aubra Eq (NDC 50102-220). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Afaxys Pharma, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure I: Mean (se) Levonorgestrel And Ethinyl Estradiol Serum Concentrations In 22 Subjects Receiving Levonorgestrel And Ethinyl Estradiol (100 Mcg Levonorgestrel And 20 Mcg Ethinyl Estradiol) (Levo Ethi Fig1)

Figure I: Mean (se) Levonorgestrel And Ethinyl Estradiol Serum Concentrations In 22 Subjects Receiving Levonorgestrel And Ethinyl Estradiol (100 Mcg Levonorgestrel And  20 Mcg Ethinyl Estradiol) (Levo Ethi Fig1)
Pharmacokinetic curves for Levonorgestrel and Ethinyl Estradiol showing concentration (ng/mL) over time (hours) on days 1, 6, and 21. The left graph depicts Levonorgestrel concentration decreasing from about 12 ng/mL to near zero over 72 hours, while the right graph shows Ethinyl Estradiol concentration decreasing from about 120 ng/mL to nearly zero over the same period, with different markers representing each day.*
FDA Label Image

Circulatory Disease Mortality Rates Per 100,000 Woman Years By Age, Smoking Status And Oral-contraceptive Use (Levo Ethi Fig2)

Circulatory Disease Mortality Rates Per 100,000 Woman Years By Age, Smoking Status And Oral-contraceptive Use (Levo Ethi Fig2)
A bar chart depicting circulatory disease mortality rates per 100,000 woman-years by age group (15-24, 25-34, 35-44, 45+) and smoking status in relation to oral contraceptive use. Four groups are compared: ever-users who are nonsmokers, control nonsmokers, ever-users who are smokers, and control smokers, showing mortality trends across these categories.*
FDA Label Image

In What Order To Take The Pills (Levo Ethi Fig3)

In What Order To Take The Pills (Levo Ethi Fig3)
A horizontal forest plot chart showing effect estimates (Odds Ratios/Relative Risks) with 95% confidence intervals from multiple studies on contraceptive use, including the NICHD, French E3N, Shanghai Women's Health, Nurses' Health II, Oxford Family Planning Association, and Danish Sex Hormone Register studies conducted between 2002 and 2017.*
FDA Label Image

Pick The Day Label Strip (Levo Ethi Fig4)

Pick The Day Label Strip (Levo Ethi Fig4)
An instructional diagram for Aubra EQ (Levonorgestrel and Ethinyl Estradiol) showing a weekly pill schedule. It includes four rows labeled 1 to 4 with circles representing daily tablets from Sunday to Saturday. The first three rows of circles are white to off-white tablets, and the fourth row shows green tablets. Arrows indicate the sequence to follow for taking the tablets. Text notes that tablets in week 4 are inactive.*
FDA Label Image

Principal Display Panel (0.1 mg/0.02 mg (28 Tablets Pouch))

Principal Display Panel (0.1 mg/0.02 mg (28 Tablets Pouch))
An instructional diagram for the Aubra EQ contraceptive kit showing how to peel and place the correct day label (MON to SUN) on the blister pack. The diagram illustrates four rows of tablets: three rows of white to off-white inactive pills and one row of green active tablets, with arrows indicating the order to take the tablets. A hand is shown peeling the correct day label to place on the kit's top edge.*
FDA Label Image

Principal Display Panel (0.1 mg/0.02 mg (Contains 3 Pouches of 28 Tablets Each))

Principal Display Panel (0.1 mg/0.02 mg (Contains 3 Pouches of 28 Tablets Each))
An instructional diagram showing the daily dosing schedule for the Aubra EQ kit containing Levonorgestrel and Ethinyl Estradiol tablets. The layout corresponds to days of the week (Sunday to Saturday) over four weeks. The first three weeks feature white to off-white tablets, while the fourth week contains green tablets. Arrows indicate the direction to follow for proper tablet intake, starting from Sunday of week 1. Week 4 tablets are inactive.*
FDA Label Image

Levo Ethi Fig7

Levo Ethi Fig7
An instructional diagram for the Aubra EQ oral contraceptive kit, showing how to select and place the correct day-of-week label onto the medication packaging. The diagram illustrates a hand placing a peel-and-stick day label on the pack with rows of pill slots labeled by days Sunday through Saturday. The illustration differentiates tablet types by color: three rows of white to off-white tablets and one row of green tablets. Arrows indicate the order to follow when taking the tablets.*
FDA Label Image

Levo Ethi Fig8

Levo Ethi Fig8
Label of Aubra EQ Levonorgestrel and Ethinyl Estradiol Tablets USP 0.1 mg/0.02 mg kit by Afaxys Pharma, LLC. The label indicates a 28-day regimen with 21 off-white active tablets and 7 green inert tablets, totaling 28 tablets in one blister card. The product is marked Rx only and includes storage instructions and manufacturer details.*
FDA Label Image

Levo Ethi Fig9

Levo Ethi Fig9
Aubra EQ Kit packaging label for Levonorgestrel and Ethinyl Estradiol tablets USP, 0.1 mg / 0.02 mg strength. The label shows the 28-day regimen with 3 pouches containing 28 tablets each, manufactured by Afaxys Pharma, LLC. The design includes blue wavy lines and a barcode, with storage and safety instructions. The labeler code and NDC 50102-220-23 are also visible.*
FDA Label Image

Chemical Structure (Levo Ethi Str)

Chemical Structure (Levo Ethi Str)
Chemical structures of Levonorgestrel and Ethinyl Estradiol, the active ingredients in Aubra EQ. The image shows detailed molecular diagrams of both compounds, labeled accordingly.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.